US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
|
04 September 2015 |
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
|
01 September 2015 |
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
|
24 August 2015 |
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
|
07 August 2015 |
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
|
05 August 2015 |
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
|
03 August 2015 |
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
|
27 July 2015 |
AstraZeneca completes agreement with Tillotts Pharma for Entocort
|
21 July 2015 |
IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
|
14 July 2015 |
AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma
|
09 July 2015 |